Long-term follow-up of mTOR inhibition for Erdheim-Chester disease-Reference-Cited by-同舟云学术

Long-term follow-up of mTOR inhibition for Erdheim-Chester disease

Published:2020-05-28 Issue:22 Volume:135 Page:1994-1997
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Pegoraro Francesco¹^ORCID,Maniscalco Valerio¹,Peyronel Francesco²^ORCID,Westenend Pieter J.³^ORCID,Hendriksz Tadek R.⁴,Roperto Rosa M.⁵,Palumbo Alessandro A.⁶,Sieni Elena⁷^ORCID,Romagnani Paola⁵⁸^ORCID,van Bommel Eric F. H.⁹,Vaglio Augusto⁵⁸

Affiliation:

1. Department of Health Sciences, University of Firenze, Florence, Italy;

2. Nephrology Unit, University Hospital, Parma, Italy;

3. Department of Pathology and

4. Department of Radiology, Albert Schweitzer Hospital, Dutch National Center of expertise for retroperitoneal fibrosis, Dordrecht, The Netherlands;

5. Nephrology and Dialysis Unit, Meyer Children’s Hospital, Florence, Italy;

6. Department of Radiology, University Hospital, Parma, Italy;

7. Department of Pediatric Hematology and Oncology, Meyer Children’s Hospital, Florence, Italy;

8. Department of Biomedical, Experimental and Clinical Sciences “Mario Serio," University of Firenze, Florence, Italy; and

9. Department of Nephrology, Albert Schweitzer Hospital, Dutch National Center of Expertise for Retroperitoneal Fibrosis, Dordrecht, The Netherlands

Abstract

Two articles this week focus on Erdheim-Chester disease (ECD), a rare histiocytosis that mainly affects adults. Clonal somatic mutations primarily involving proteins in the BRAF and MPAK pathways have established ECD as a myeloid neoplasm, with targeted therapies now available for patients. In the first paper, an international panel presents new consensus recommendations for evaluation and treatment of ECD. In the second paper, Pegoraro and colleagues present long-term outcomes of patients with ECD treated with sirolimus, with responses in patients both with and without BRAF mutations.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/135/22/1994/1736017/bloodbld2019004478r1.pdf

Reference25 articles.

1. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages;Emile;Blood,2016

2. Histiocytoses: emerging neoplasia behind inflammation;Haroche;Lancet Oncol,2017

3. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation;Hervier;Blood,2014

4. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults;Milne;Blood,2017

5. Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells;Durham;Blood,2017

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Erdheim–Chester Disease Due to a Novel Internal Duplication of NRAS: Response to Targeted Therapy with Cobimetinib;International Journal of Molecular Sciences;2023-10-23

2. Childhood-onset Erdheim-Chester disease in the molecular era: clinical phenotypes and long-term outcomes of 21 patients;Blood;2023-09-28

3. H syndrome mimicking Erdheim Chester disease: new entity and therapeutic perspectives;Haematologica;2023-02-02

4. Clinical phenotypes and long-term outcome of kidney involvement in Erdheim-Chester histiocytosis;Kidney International;2023-01

5. Rare presentation of multiple thromboses in Erdheim–Chester disease: a case-based review;International Journal of Hematology;2022-06-10